Axon Neuroscience SE
6
0
0
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1
Role: collaborator
Alzheimer's Tau Platform: Regimen A - AADvac1
Role: collaborator
A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia
Role: lead
24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease
Role: lead
18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease
Role: lead
Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease
Role: lead
All 6 trials loaded